These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29724879)

  • 1. Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures.
    Wang GS; Severtson SG; Bau GE; Dart RC; Green JL
    Pediatrics; 2018 Jun; 141(6):. PubMed ID: 29724879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine-Naloxone Tablets.
    Hampp C; Lovegrove MC; Budnitz DS; Mathew J; Ho A; McAninch J
    Drug Saf; 2020 Feb; 43(2):189-191. PubMed ID: 31745829
    [No Abstract]   [Full Text] [Related]  

  • 3. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.
    Lavonas EJ; Banner W; Bradt P; Bucher-Bartelson B; Brown KR; Rajan P; Murrelle L; Dart RC; Green JL
    J Pediatr; 2013 Nov; 163(5):1377-83.e1-3. PubMed ID: 23993129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine Exposures Among Children and Adolescents Reported to US Poison Control Centers.
    Post S; Spiller HA; Casavant MJ; Chounthirath T; Smith GA
    Pediatrics; 2018 Jul; 142(1):. PubMed ID: 29941678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center.
    Toce MS; Burns MM; O'Donnell KA
    Clin Toxicol (Phila); 2017 Jan; 55(1):12-17. PubMed ID: 27756148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
    Butler SF; Black RA; Severtson SG; Dart RC; Green JL
    J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone.
    Pedapati EV; Bateman ST
    Pediatr Crit Care Med; 2011 Mar; 12(2):e102-7. PubMed ID: 20921918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine prescribing practices and exposures reported to a poison center--Utah, 2002-2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(49):997-1001. PubMed ID: 23235296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of pediatric buprenorphine and methadone exposures reported to the poison centers.
    Rege SV; Ngo DA; Ait-Daoud N; Rizer J; Sharma S; Holstege CP
    Ann Epidemiol; 2020 Feb; 42():50-57.e2. PubMed ID: 31992493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003-2019.
    Darracq MA; Thornton SL
    Clin Toxicol (Phila); 2021 Apr; 59(4):303-312. PubMed ID: 32894033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008-2015.
    Budnitz DS; Lovegrove MC; Sapiano MR; Mathew J; Kegler SR; Geller AI; Hampp C
    MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1148-1149. PubMed ID: 27764078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Food and Drug Administration Mandate to Limit Acetaminophen in Prescription Combination Products.
    Goldberger D; Vearrier D
    J Med Toxicol; 2017 Dec; 13(4):303-308. PubMed ID: 28710607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unintentional methadone and buprenorphine exposures in children: Developing prevention messages.
    Schwartz L; Mercurio-Zappala M; Howland MA; Hoffman RS; Su MK
    J Am Pharm Assoc (2003); 2017; 57(2S):S83-S86. PubMed ID: 28292505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of Poison Center Exposures for Pediatric Accidental Unsupervised Ingestions of Acetaminophen after the Introduction of Flow Restrictors.
    Brass EP; Reynolds KM; Burnham RI; Green JL
    J Pediatr; 2018 Jul; 198():254-259.e1. PubMed ID: 29622340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the prescription opioid epidemic on young children: Trends and mortality.
    Wang GS; Olsen H; Severtson G; Green JL; Dart RC
    Drug Alcohol Depend; 2020 Jun; 211():107924. PubMed ID: 32178937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow Restrictors and Reduction of Accidental Ingestions of Over-the-Counter Medications.
    Paul IM; Reynolds KM; Delva-Clark H; Burnham RI; Green JL
    Am J Prev Med; 2019 Jun; 56(6):e205-e213. PubMed ID: 31003808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
    Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
    J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.